Bollu, V., Ernst, F.R., Karafilidis, J., Rajagopalan, K., Robinson, S.B. and Braman, S.S. (2013) Hospital Readmissions Following Initiation of Nebulized Arformoterol Tartrate or Nebulized Short-Acting Beta-Agonists among Inpatients Treated for COPD. International Journal of Chronic Obstructive Pulmonary Disease, 8, 631-639. http://dx.doi.org/10.2147/COPD.S52557

has been cited by the following article:

• TITLE: Research Advance in the Efficacy and Mechanism of Qing Fei Xiao Yan Wan for the Treatment of Respiratory Diseases

  AUTHORS: Junying Ding, Qingquan Liu

  KEYWORDS: Qing Fei Xiao Yan Wan, Clinical Trials, Experiment Studies, Mechanism, Efficacy

  JOURNAL NAME: Modern Research in Inflammation, Vol.3 No.3, August 12, 2014

  ABSTRACT: Qing Fei Xiao Yan Wan had been incorporated into the existing “Chinese Pharmacopoeia”, protected by patents. The manufacturing process of it was scientific and its compatibility was reasonable. It was also shown by clinical trials that the efficacy is exact. Clinical trials and experiment studies had confirmed the efficacy and some mechanism for the treatment of respiratory diseases, which were summaried in this paper. Combined with the experimental results (published in another paper), the other prospect application was further discussed.